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PPercutaneous Intervention and Renal Dysfunction
ontrast-Induced Nephropathy
n Patients Undergoing Primary
ngioplasty for Acute Myocardial Infarction
iancarlo Marenzi, MD, Gianfranco Lauri, MD, Emilio Assanelli, MD, Jeness Campodonico, MD,
onica De Metrio, MD, Ivana Marana, MD, Marco Grazi, MD, Fabrizio Veglia, PHD,
ntonio L. Bartorelli, MD, FACC
ilan, Italy
OBJECTIVES The aim of this research was to assess the incidence, clinical predictors, and outcome of
contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (PCI)
for acute myocardial infarction (AMI).
BACKGROUND Contrast-induced nephropathy is associated with significant morbidity and mortality after
PCI. Patients undergoing primary PCI may be at higher risk of CIN because of hemody-
namic instability and unfeasibility of adequate prophylaxis.
METHODS In 208 consecutive AMI patients undergoing primary PCI, we measured serum creatinine
concentration (Cr) at baseline and each day for the following three days. Contrast-induced
nephropathy was defined as a rise in Cr 0.5 mg/dl.
RESULTS Overall, CIN occurred in 40 (19%) patients. Of the 160 patients with baseline Cr clearance
60 ml/min, only 21 (13%) developed CIN, whereas it occurred in 19 (40%) of those with
Cr clearance 60 ml/min (p  0.0001). In multivariate analysis, age 75 years (odds ratio
[OR] 5.28, 95% confidence interval [CI] 1.98 to 14.05; p  0.0009), anterior infarction (OR
2.17, 95% CI 0.88 to 5.34; p  0.09), time-to-reperfusion 6 h (OR 2.51, 95% CI 1.01 to
6.16; p  0.04), contrast agent volume 300 ml (OR 2.80, 95% CI 1.17 to 6.68; p  0.02)
and use of intraaortic balloon (OR 15.51, 95% CI 4.65 to 51.64; p  0.0001) were
independent correlates of CIN. Patients developing CIN had longer hospital stay (13  7
days vs. 8  3 days; p  0.001), more complicated clinical course, and significantly higher
mortality rate (31% vs. 0.6%; p  0.001).
CONCLUSIONS Contrast-induced nephropathy frequently complicates primary PCI, even in patients with
normal renal function. It is associated with higher in-hospital complication rate and mortality.
Thus, preventive strategies are needed, particularly in high-risk patients. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.043Cardiol 2004;44:1780–5) © 2004 by the American College of Cardiology Foundation
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wontrast-induced nephropathy (CIN) is a possible compli-
ation of coronary diagnostic and interventional procedures.
ts development has been associated with increased in-
ospital and long-term morbidity and mortality, prolonged
ospitalization, and long-term renal impairment (1–7).
everal risk factors for CIN have been identified. Chronic
enal insufficiency, diabetes mellitus, congestive heart fail-
re, intravascular volume depletion, and the use of a large
mount of contrast agent are considered important predis-
osing factors (5,7,8).
Increasing evidence exists that primary percutaneous
oronary intervention (PCI) obtains rapid restoration of
oronary artery patency and increases threatened myocar-
ium salvage, thus preserving ventricular function and
mproving survival of patients with acute myocardial infarc-
ion (AMI) (9,10). However, patients treated with primary
CI may represent a population at higher risk for CIN than
hose undergoing elective PCI. Several conditions may
From the Centro Cardiologico Monzino, I.R.C.C.S., Institute of Cardiology of the
niversity of Milan, Milan, Italy.i
Manuscript received February 20, 2004; revised manuscript received July 22, 2004,
ccepted July 28, 2004.ontribute to renal injury in this setting. Among them,
ypotension or even shock, a large volume of contrast
edia, and the impossibility of starting a renal prophylactic
herapy are the factors most likely involved. The impact of
hese factors on renal function, and the clinical relevance of
IN in the setting of primary PCI remain unknown, but are
hought to be considerable. Only recently have studies
emonstrated that renal insufficiency and AMI represent a
igh-risk combination (11). Moreover, other clinical obser-
ations have shown that renal dysfunction is an independent
isk factor for death in AMI patients (12–14).
The purpose of this prospective study was to determine
he incidence, the clinical predictors, and the clinical con-
equences of CIN development in an unselected population
f consecutive patients undergoing primary PCI for AMI.
ETHODS
tudy population. Between January 1, 2001, and June 30,
003, we enrolled all consecutive patients admitted to our
oronary care unit (CCU) for ST-segment elevation AMI
ho were treated with primary PCI. According to our
nstitute protocol, patients were included if they presented
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November 2, 2004:1780–5 Contrast Nephropathy After Primary PCIithin 12 h (18 h for AMI complicated by cardiogenic
hock) from the onset of symptoms (characteristic chest
ain lasting for at least 30 min, not responsive to nitrates,
ith electrocardiographic ST-segment elevation of at least
.2 mV in two or more contiguous leads, or left bundle-
ranch block). Patients were excluded if the coronary
natomy was not suitable for PCI or if emergency bypass
rafting was required. Patients in chronic peritoneal or
emodialytic treatment were also excluded. The study was
pproved by the ethics committee of our institution, and
nformed consent was obtained from all patients.
tudy protocol. After contrast exposure, physiologic
0.9%) saline was given intravenously at a rate of 1 ml/kg/h
or 12 h. In patients with left ventricular dysfunction
ejection fraction 40%) or overt heart failure, the hydra-
ion rate was reduced to 0.5 ml/kg/h. The use of beta-
drenergic blocking agents, angiotensin-converting enzyme
nhibitors, platelet glycoprotein IIb/IIIa receptor inhibitors
abciximab), diuretics, or the indication to intraaortic bal-
oon pump or inotropic drugs support, was left to the
iscretion of the interventional and CCU cardiologists,
ccording to our institute’s clinical protocols and interna-
ional experience guidelines (15). An echocardiographic
valuation was performed in all patients within 12 h from
ospital admission. Serum creatinine concentration (Cr)
as measured at the time of admission (just before primary
CI), every day for the following three days, and at
ischarge from the CCU. Creatinine clearance was calcu-
ated by applying the Cockcroft-Gault formula to the Cr
16). During hospitalization the following adverse clinical
vents were considered: major bleeding requiring 2 U of
lood, acute pulmonary edema, acute renal failure requiring
mergency renal replacement therapy (hemofiltration or
emodialysis), cardiogenic shock, tachyarrhythmias and
radyarrhythmias, and death.
rimary PCI. Primary PCI was performed by a 24-h
n-call interventional team, according to standard clinical
ractice, using the femoral approach and 7-F guiding
atheters. Type of contrast agent and contrast dose, angio-
lasty technique, and supportive pharmacologic therapies
ere left to the discretion of the interventional cardiologist.
atients received a bolus of 5,000 U heparin in the CCU,
ollowed by an additional bolus during the procedure, if
eemed necessary.
efinitions. Contrast-induced nephropathy was defined as
Abbreviations and Acronyms
AMI  acute myocardial infarction
CCU  coronary care unit
CI  confidence interval
CIN  contrast-induced nephropathy
Cr  serum creatinine concentration
OR  odds ratio
PCI  percutaneous coronary interventionn absolute increase in Cr 0.5 mg/dl after PCI (17). according to our clinical protocol, emergency renal-
eplacement therapy (hemofiltration or hemodialysis) was
erformed if there was oligoanuria for more than 48 h,
espite the administration of more than 1 g of intravenous
urosemide per 24 h. Emergency renal-replacement therapy
as performed earlier in the event of concomitant overt
eart failure (18). Blood transfusion was initiated in case of
emoglobin reduction below 8.0 g/l. Time-to-reperfusion
as measured as the time from symptom onset to coronary
eperfusion obtained with balloon inflation. Cardiogenic
hock was defined as prolonged hypotension (systolic blood
ressure 85 mm Hg) with evidence of decreased organ
erfusion caused by severe left ventricular dysfunction, right
entricular infarction, or mechanical complications of in-
arction and not due to hypovolemia, bradyarrhythmias, or
achyarrhythmias.
tatistical analysis. Continuous data are reported as the
ean value  SD, unless otherwise specified. Categorical
ata are presented as absolute values and percentages.
omparison of continuous variables was performed by
eans of Student t test. Chi-square and Fisher exact tests
ere used for comparison of categorical variables as appro-
riate. The trend of CIN incidence and in-hospital mortal-
ty according to ordinal variables was assessed by the
antel-Haenszel chi-square for trend. A multivariable
ogistic regression model was applied including all the
otential confounding variables (i.e., age75 years, anterior
MI, time-to-reperfusion 6 h, contrast agent volume
300 ml, and use of intraaortic balloon pump). A p value
0.05 was considered statistically significant. Analyses were
onducted using SAS statistical software (Version 8.02,
AS Institute Inc., Cary, North Carolina).
ESULTS
ncidence of CIN and clinical characteristics. Of a total
f 218 AMI patients, 10 were excluded (7 because there was
o indication for PCI, 2 who were treated with coronary
ypass surgery because of coronary anatomy not suitable for
CI, and 1 because of chronic dialysis). Hence, a total of
08 patients (165 men, 43 women; mean age 62 11 years)
ere included in this study. Of them, 40 (19%) developed
IN. The incidence of this complication was 17% when
atients with baseline increased Cr (1.5 mg/dl) were
xcluded. Table 1 shows the baseline clinical and procedural
haracteristics of patients who developed CIN and of those
ho did not present this complication after primary PCI.
atients developing CIN were older and more frequently
ad anterior AMI, higher baseline Cr value, longer time-
o-reperfusion, higher enzymatic peak, and lower left ven-
ricular ejection fraction. In addition, they received a higher
olume of the contrast agent during PCI than patients
ithout CIN. Of note, contrast volume was higher in
nterior AMI (335  158 ml) compared with inferior AMI
270  128 ml; p  0.001). In 11 (5%) of the 208 patients,
bnormal Cr (1.5 mg/dl) was present at hospital admis-
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Contrast Nephropathy After Primary PCI November 2, 2004:1780–5ion. Seven of these patients had no history of pre-existing
enal insufficiency; this suggests that the increased Cr value
as likely due to changes in renal hemodynamics associated
ith impaired systemic perfusion during the acute cardiac
vent. When creatinine clearance was estimated (16), 48
23%) of the 208 patients had a moderately impaired renal
unction (60 ml/min). Of them, 19 (40%) developed CIN.
n contrast, of the 160 patients with a baseline Cr clearance
alue 60 ml/min, only 21 (13%) developed CIN after
rimary PCI (p  0.0001).
Figure 1 shows the Cr values in the two groups during the
CU stay. When the maximal Cr increase versus baseline
as considered, regardless of the time point of occurrence,
mean value of 106 93% was found in patients with CIN
nd of 8  13% in patients without CIN.
he relation of CIN with in-hospital outcome. Patients
ith CIN experienced a more complicated in-hospital
linical course (Table 2). All of the major adverse clinical
vents occurred more frequently in this group. Furthermore,
he average length of hospital stay in patients with CIN was
pproximately 1.5  longer than that in patients without
IN (13 7 days vs. 8 3 days; p 0.001). Nine patients
one with CIN and eight without CIN) underwent elective
oronary bypass after successful primary PCI to complete
oronary revascularization; the length of their in-hospital
eriod was not considered.
Table 1. Baseline Clinical and Procedural Cha
C
(n
Age (yrs) 67
Age 75 yrs 14 (3
Men 36 (9
Smokers 17 (4
Diabetes mellitus 3 (7
Hypertension 21 (5
Dyslipidemia 7 (1
Previous myocardial infarction 10 (2
Previous CABG 3 (7
Anterior infarction 29 (7
Time-to-reperfusion (h) 5.6
Mean LVEF (%) 41
LVEF 40% 20 (5
Serum creatinine (mg/dl)† 1.2 (1
Serum creatinine 1.5 mg/dl 7 (1
Creatinine clearance (ml/min) 61
Highest total creatine kinase (IU/l) 3,445
Culprit lesion
Left anterior descending 30 (7
Left circumflex 2 (5
Right coronary artery 8 (2
Bypass graft 0 (0
Coronary stenting 39 (9
Abciximab 19 (4
Contrast volume (ml) 378
Contrast volume 300 ml 26 (6
*By Fisher exact test; †median and interquartile ranges; ‡by
CABG  coronary artery bypass graft surgery; CIN 
fraction; PCI  percutaneous coronary intervention.The overall in-hospital mortality in the entire population
b
cas 6.2% (n  13). However, the mortality rate was
ignificantly higher in patients developing CIN. Indeed, 12
31%) patients died in the CIN group (5 for cardiogenic
hock, 3 for multiorgan failure, 2 for refractory heart failure,
for sudden death, and 1 for ischemic stroke), whereas only
death (0.6%; p  0.0001) occurred in the group without
IN, due to left ventricular free-wall rupture with cardiac
amponade.
ristics of the Study Patients
No CIN
(n  168) p Value
61  11 0.002
17 (10%) 0.0001
129 (77%) 0.06
93 (55%) 0.14
20 (12%) 0.58*
68 (42%) 0.17
54 (32%) 0.07
22 (13%) 0.06
4 (2%) 0.0011*
77 (46%) 0.0015
3.8  2.4 0.0001
51  9 0.0001
18 (11%) 0.0001
6) 1.0 (0.9–1.15) 0.0001‡
4 (2%) 0.0001
80  24 0.0001
48 1,897  1,786 0.0001
0.003*
72 (43%)
29 (17%)
64 (38%)
3 (2%)
165 (98%) 0.76
86 (51%) 0.67
0 286  125 0.008
65 (39%) 0.003
rametric Wilcoxon rank test.
st-induced nephropathy; LVEF  left ventricular ejection
igure 1. Median and interquartile ranges of serum creatinine concentra-
ion in patients developing (squares) and in those not developing (circles)
ontrast-induced nephropathy after primary angioplasty. Data are shown atracte
IN
 40)
 12
6%)
0%)
2%)
%)
2%)
7%)
5%)
%)
2%)
 2.7
 11
0%)
.1–1.3
7%)
 19
 2,4
7%)
%)
0%)
%)
7%)
8%)
 20
5%)
nonpaaseline, during the following three days, and at discharge from the
oronary care unit (CCU).
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November 2, 2004:1780–5 Contrast Nephropathy After Primary PCIndependent correlates of CIN. In multivariate analysis,
he following variables remained significant independent
orrelates of CIN: age 75 years (odds ratio [OR] 5.28,
5% confidence interval [CI] 1.98 to 14.05; p  0.0009),
nterior AMI (OR 2.17, 95% CI 0.88 to 5.34; p  0.09),
ime-to-reperfusion 6 h (OR 2.51, 95% CI 1.01 to 6.16;
 0.04), contrast agent volume 300 ml (OR 2.80, 95%
I 1.17 to 6.68; p  0.02), and use of intra-aortic balloon
ump (OR 15.51, 95% CI 4.65 to 51.64; p  0.0001).
Using these variables as risk indicators for CIN, we
eveloped a risk scoring system. A value of 1 was assigned
hen a factor was present, and 0 when it was absent. For
ach patient, the score was calculated as the sum of the
umber of independent variables (range 0 to 5) recorded in
he initial hours of hospital stay (at admission and at the end
f primary PCI). The incidence of CIN (Fig. 2), as well as
he in-hospital mortality rate (Fig. 3), revealed a significant
radation as the risk score increased in the study population.
Table 2. In-Hospital Clinical Complications
CPR, VT, or VF
High-rate atrial fibrillation
High-degree conduction disturbances requiring
permanent pacemaker
Acute pulmonary edema
Respiratory failure requiring mechanical
ventilation
Cardiogenic shock requiring intra-aortic
balloon counterpulsation
Major bleeding requiring blood transfusion
Acute renal failure requiring renal replacement
therapy
Patients with two or more clinical
complications
*By Fisher exact test.
CIN  contrast-induced nephropathy; CPR  cardio
ventricular tachycardia.igure 2. Incidence of contrast-induced nephropathy (CIN) in study
atients according to the risk score. p  0.0001.
F
rISCUSSION
his study demonstrates that CIN is a frequent complica-
ion after primary PCI in AMI, even in patients with
ormal baseline renal function, and is associated with
ncreased in-hospital morbidity, mortality, and prolonged
ospitalization.
Growing evidence indicates that primary PCI is the most
ffective treatment of AMI, and many studies have demon-
trated both that ventricular function is preserved and that
urvival improved when AMI patients with acute ST-
egment elevation undergo this therapeutic approach (9,10).
he aim of reperfusion therapy in AMI is to reduce
ortality and morbidity, and this goal is best achieved when
atency of the infarct-related coronary artery is obtained as
arly as possible. In our study population, the in-hospital
ortality rate was 6.2%, a value comparable with those
eported in larger clinical trials (10). In this prospective
nalysis, we have focused our evaluation on the development
f CIN during AMI as a possible complication of primary
CIN
(n  40)
No CIN
(n  168) p Value
3 (8%) 7 (4%) 0.41*
6 (15%) 6 (4%) 0.01*
2 (5%) 0 (0%) 0.04*
5 (13%) 3 (2%) 0.008*
8 (20%) 2 (1%) 0.0001*
13 (33%) 7 (4%) 0.0001*
4 (10%) 5 (3%) 0.07*
6 (15%) 0 (0%) 0.0001*
14 (35%) 4 (3%) 0.0001*
nary resuscitation; VF  ventricular fibrillation; VT igure 3. Incidence of in-hospital death in study patients according to the
isk score. p  0.0001.
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Contrast Nephropathy After Primary PCI November 2, 2004:1780–5CI. Acute renal deterioration occurred in 19% of all
atients undergoing primary PCI, and was a strong predic-
or of in-hospital morbidity and mortality. Patients with
IN had a more prolonged and complicated clinical course
nd a strikingly higher in-hospital mortality (31%). It is
oteworthy that the in-hospital mortality of patients who
id not develop CIN after primary PCI was only 0.6%.
Most of our patients had a normal renal function before
hey experienced the acute coronary event. Nevertheless, the
n-hospital mortality rate of those who developed CIN
pproached, or was even greater than, that observed in
hronic renal failure patients undergoing elective PCI
6,19), and in patients with chronic renal failure admitted
ith AMI to a CCU (11–13,20). On the other hand,
atients with normal renal function undergoing elective
CI have a significantly lower incidence of CIN (1.2% to
.6%) than our study population (17%) who had normal Cr
t hospital presentation (1,8). Patients with baseline chronic
enal failure were only a minority of our population. Thus,
o final conclusion can be drawn from their outcome. There
re few doubts that poorer clinical outcome can be expected
n such patients. Recent results from a clinical study and
ata from the New York State angioplasty registry showed
hat baseline Cr and end-stage renal disease are independent
isk factors for death after primary PCI (14,21). When
reatinine clearance was calculated in our population, a
reater number of patients showed reduced baseline renal
unction (creatinine clearance 60 ml/min). The incidence
f CIN was higher in these patients as compared with those
ith preserved renal function (40% vs. 13%).
An increased CIN risk has been reported in patients with
hronic renal failure subjected to an early invasive approach
or acute coronary syndromes without ST-segment eleva-
ion (22,23). In such a population, prophylaxis for CIN is
ossible, and hemodynamic stability is usually obtained
efore PCI. In contrast, there is no possibility to perform
dequate hydration in AMI patients undergoing primary
CI.
Our data strengthen the crucial link between cardiac and
enal dysfunction, and extend the observation of the nega-
ive impact on survival deriving from the association be-
ween cardiac and renal disease to patients with AMI
ndergoing primary PCI. Renal function is a major deter-
inant of cardiovascular outcome in a variety of settings,
ncluding hypertension (24), chronic heart failure (25,26),
cute coronary syndromes (12,23,27,28), AMI (11–14,29),
lective PCI (1–7,19), surgical coronary revascularization
30,31), and, more generally, in patients referred to a CCU
or any reason (32). This study demonstrates that patients
ndergoing primary PCI for AMI represent a population at
igher risk for CIN, despite the fact that most of them have
o history or evidence of pre-existing renal insufficiency.
One strength of this study is that we identified several
ndependent variables for CIN development after primary
CI. In particular, old age (75 years), anterior AMI, large
300 ml) contrast volume exposure (33), use of intra- aortic balloon pump, and a longer (6 h) time-to-
eperfusion were associated with an increased risk of CIN
ccurrence and a higher mortality rate. Interestingly, the
ontrast volume needed to perform PCI was higher in
nterior compared with inferior AMI. Differences between
eft and right coronary anatomy and procedural aspects may
xplain this finding.
Innovative preventive strategies aimed at protecting the
idneys from contrast toxicity and ischemic burden during
he acute phase of infarction need to be developed and
ested, even in patients with normal renal function. Prophy-
actic measures will be particularly relevant in patients with
n elevated CIN risk score. Although this simple risk score
hould be tested in an independent and not in a “learning
opulation,” it may have wide applicability, and can be easily
alculated in the initial hours of hospital presentation in
rder to predict the risk of CIN and the associated higher
dverse event rate in AMI patients undergoing primary
CI. Moreover, it may help to better identify those patients
ost likely to benefit from a renal-protective intervention.
n this regard, saline hydration infusion, performed soon
fter PCI and prolonged for 12 h, had no major impact on
IN prevention in our patients. Newer pharmacologic (34)
r nonpharmacologic (35,36) strategies that showed a ben-
fit in terms of CIN prevention among patients undergoing
lective PCI should be evaluated also in high-risk AMI
atients treated with primary PCI.
tudy limitations. Our study has some limitations. First,
ur study included a small population, admitted to a single
enter. Our findings should be confirmed and the applica-
ion of the risk score validated in a large multicenter trial.
econd, the definition of CIN is based on the absolute or
elative increase in Cr level, compared with baseline value,
fter a patient has been exposed to a contrast agent, when
lternative explanations for renal impairment have been
xcluded (37). Although all our patients effectively under-
ent contrast media exposure, and 19% developed acute
enal failure within 48 h to 72 h after it, we cannot exclude
he possibility that other factors, such as hemodynamic
nstability, might have contributed, at least in part, to renal
mpairment, and influenced the clinical outcome of our
atients. Indeed, in addition to contrast agent volume, other
actors reflecting cardiocirculatory impairment, such as an-
erior AMI, long time-to-reperfusion, and need for in-
raaortic balloon pump, were independently related to the
evelopment of renal dysfunction. This suggests that kidney
ypoperfusion, resulting in ischemic renal injury, might play
major role. However, despite the fact that no firm
onclusions can be drawn at this stage, our data suggest that
he potential exists for further reduction of mortality after
rimary PCI. This could probably be obtained on one hand
hrough newer therapies, aimed at preventing acute renal
ysfunction, and on the other by shortening time-to-
eperfusion and minimizing contrast volume.
onclusions. In the era of primary PCI for AMI, CIN is
frequent complication, even in patients with normal renal
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November 2, 2004:1780–5 Contrast Nephropathy After Primary PCIunction, and is associated with a more complicated in-
ospital course and very high mortality rate. Thus, newer
reventive strategies of renal protection during primary PCI
re warranted, particularly in high-risk patients.
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